Loading...
Time‐to‐Event Analysis of Polatuzumab Vedotin‐Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens
Polatuzumab vedotin, an antibody‐drug conjugate containing monomethyl auristatin E, was associated with an incidence of grade ≥2 peripheral neuropathy (PN) of 55–72% in patients with indolent non‐Hodgkin lymphoma in a phase II study, when dosed 1.8–2.4 mg/kg every 3 weeks until progression or for a...
Na minha lista:
| Udgivet i: | CPT Pharmacometrics Syst Pharmacol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5488137/ https://ncbi.nlm.nih.gov/pubmed/28544534 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12192 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|